

09/413109

WEST

Search results

for Pages # 32

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

Search Results -

Terms	Documents
L5 and pharmaceutic\$	101

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L6

Refine Search

Recall Text

Clear

Search History
DATE: Saturday, March 29, 2003 [Printable Copy](#) [Create Case](#)
Set Name Query
 side by side

Hit Count Set Name
 result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L6</u>	L5 and pharmaceutic\$	101	<u>L6</u>
<u>L5</u>	L4 and apoptosis	117	<u>L5</u>
<u>L4</u>	L2 and adenovir\$ near10 (intratrach\$ or intravenou\$ or inject\$)	206	<u>L4</u>
<u>L3</u>	L2 and p53 near10 (CMV or cytomegalovirus)	69	<u>L3</u>
<u>L2</u>	L1 and p53	1839	<u>L2</u>
<u>L1</u>	adenovir\$ near5 vector\$	9336	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 100 of 101 returned.**

-
- ☐ 1. 20030060434 . 13 May 99. 27 Mar 03. COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS. NIELSEN, LORETTA, et al. 514/44; A61K048/00.
-
- ☐ 2. 20030059794 . 05 Mar 02. 27 Mar 03. Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds. Vogels, Ronald, et al. 435/6; 435/456 435/7.2 435/8 C12Q001/68 G01N033/53 G01N033/567 C12Q001/66 C12N015/861.
-
- ☐ 3. 20030053991 . 23 Sep 02. 20 Mar 03. Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders. Kingsman, Alan John, et al. 424/93.2; 435/235.1 435/320.1 435/368 435/456 A61K048/00 C12N007/00 C12N015/867 C12N005/08.
-
- ☐ 4. 20030053989 . 14 Sep 01. 20 Mar 03. Method of modulating neovascularization. Kovesdi, Imre. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861.
-
- ☐ 5. 20030045499 . 09 Aug 02. 06 Mar 03. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses. Gabrilovich, Dmitry, et al. 514/44; A61K048/00.
-
- ☐ 6. 20030044383 . 10 Sep 98. 06 Mar 03. TISSUE SPECIFIC ADENOVIRAL VECTORS. HENDERSON, DANIEL R., et al. 424/93.2; 435/320.1 435/325 435/440 435/455 514/44 A61K048/00 C12P021/02 C12N005/06 C12N015/87.
-
- ☐ 7. 20030039998 . 22 May 02. 27 Feb 03. Method for regulating cell growth and assays related thereto. Gelfand, Erwin W., et al. 435/6; 435/7.23 435/91.2 C12Q001/68 G01N033/574 C12P019/34.
-
- ☐ 8. 20030021796 . 02 May 02. 30 Jan 03. Method of enhancing T cell immunity by selection of antigen specific T cells. Ignatowicz, Leszek, et al. 424/185.1; 424/186.1 424/190.1 424/191.1 A61K039/00 A61K039/12 A61K039/02 A61K039/002.
-
- ☐ 9. 20030021767 . 25 Jun 02. 30 Jan 03. Recombinant p53 adenovirus methods and compositions. Zhang, Wei-Wei, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 10. 20030012770 . 11 Jun 02. 16 Jan 03. Recombinant p53 adenovirus methods and compositions. Zhang, Wei-Wei, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.
-
- ☐ 11. 20030003076 . 30 Jul 01. 02 Jan 03. Adenovirus E1B-55K single amino acid mutants and methods of use. Shen, Yuqiao, et al. 424/93.2; 435/235.1 435/456 536/23.1 A61K048/00 C12N007/00 C07H021/02 C12N015/861.
-
- ☐ 12. 20020187143 . 16 Aug 02. 12 Dec 02. Methods and compositions for reducing immune response. LaFace, Drake M., et al. 424/140.1; 435/320.1 536/23.72 A61K039/395 A61K039/00 C07H021/04 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 13. 20020183271 . 07 Dec 01. 05 Dec 02. Methods of treatment involving human MDA-7. Chada, Sunil, et al. 514/44; 424/94.1 A61K048/00 A61K038/43.
-
- ☐ 14. 20020177551 . 30 May 01. 28 Nov 02. Compositions and methods for treatment of

neoplastic disease. Terman, David S.. 514/12; 435/325 530/350 A61K038/17 C12N005/06 C07K014/705.

☐ 15. 20020177207 . 14 Mar 02. 28 Nov 02. Tsg101-interacting proteins and use thereof. Sugiyama, Janice, et al. 435/196; 435/199 435/226 C12N009/16 C12N009/22 C12N009/64.

☐ 16. 20020173026 . 14 Mar 02. 21 Nov 02. Survivin-interacting proteins and use thereof. Wettstein, Daniel Albert, et al. 435/199; 435/226 435/320.1 435/325 435/69.1 C12N009/22 C12N009/64 C12P021/02 C12N005/06.

☐ 17. 20020169121 . 14 Feb 02. 14 Nov 02. Inhibition of ATF2 activity to treat cancer. Ronai, Ze'ev, et al. 514/12; A61K038/17.

☐ 18. 20020165195 . 01 May 02. 07 Nov 02. Method of treating androgen-dependent disorders. Wang, Lynn, et al. 514/44; 424/94.4 A61K048/00 A61K038/44.

☐ 19. 20020164799 . 02 Jul 01. 07 Nov 02. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little, Andrew S., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/00.

☐ 20. 20020164715 . 10 Jul 01. 07 Nov 02. Chromosome 3p21.3 genes are tumor suppressors. Ji, Lin, et al. 435/69.5; 435/320.1 435/325 530/351 536/23.5 C12P021/02 C07H021/04 C12N005/06 C07K014/525.

☐ 21. 20020155127 . 01 Nov 01. 24 Oct 02. Genetic vaccine against human immunodeficiency virus. Wang, Danher. 424/199.1; 424/202.1 424/208.1 424/233.1 435/235.1 435/320.1 A61K039/12 C12N007/00 A61K039/295 A61K039/21 A61K039/23 A61K039/235 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.

☐ 22. 20020151461 . 22 Dec 99. 17 Oct 02. MODIFIED RETINOBLASTOMA TUMOR SUPPRESSOR PROTEINS. XU, HONG-JI, et al. 514/2; 514/1 514/42 514/43 514/44 A61K031/00 A01N061/00 A01N037/18 A61K038/00 A61K031/70 A01N043/04.

☐ 23. 20020150557 . 30 Jan 02. 17 Oct 02. Selectively replicating viral vectors. Ramachandra, Muralidhara, et al. 424/93.2; 424/456 435/320.1 A61K048/00 C12N015/861.

☐ 24. 20020147173 . 24 May 02. 10 Oct 02. Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodies. Kaelin, William, et al. 514/44; 435/7.23 530/388.26 530/388.8 A61K048/00 G01N033/574 C07K016/30 C07K016/40.

☐ 25. 20020143142 . 04 Apr 02. 03 Oct 02. Sequence and method for genetic engineering of proteins with cell membrane translocating activity. Lin, Yao-Zhong, et al. 530/324; 435/320.1 435/325 435/69.1 530/325 530/326 530/327 536/23.1 C07K014/435 C07K007/08 C12P021/02 C12N005/06 C07H021/04.

☐ 26. 20020137212 . 18 May 01. 26 Sep 02. Adenoviral vectors having a protein IX deletion. Gregory, Richard J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/01.

☐ 27. 20020123477 . 03 Aug 01. 05 Sep 02. Enhanced expression of transgenes. Cristiano, Richard J., et al. 514/44; 514/105 514/34 514/410 514/492 514/589 514/8 A61K048/00 A61K038/17 A61K031/66 A61K031/407 A61K031/175 A61K031/28.

☐ 28. 20020120121 . 09 Oct 01. 29 Aug 02. Detection and modulation of IAPs and NAIP for the

diagnosis and treatment of proliferative disease. Korneluk, Robert G., et al. 536/23.2; A61K048/00 C07H021/04.

☐ 29. 20020120117 . 21 Mar 01. 29 Aug 02. Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof. Yu, De-Chao, et al. 536/23.2; 435/320.1 435/325 435/69.1 C12P021/02 C07H021/04 C12N005/06.

☐ 30. 20020115081 . 21 Aug 01. 22 Aug 02. Diagnosis and treatment of cardiovascular conditions. Lee, Richard T., et al. 435/6; 435/7.21 514/12 C12Q001/68 G01N033/567 A61K038/17.

☐ 31. 20020106746 . 04 Oct 01. 08 Aug 02. Anti-inflammatory vectors. Rooke, Ronald. 435/91.33; 424/199.1 424/204.1 424/233.1 424/93.21 435/235.1 435/320.1 435/456 435/91.41 530/388.7 536/23.72 A61K048/00 C12N007/00 C12N015/861 C07H021/04 C12P019/34 C12N015/64 C12N015/66 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C07K016/00 C12P021/08 C12N015/86.

☐ 32. 20020102731 . 12 Feb 01. 01 Aug 02. Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof. Hearing, Patrick, et al. 435/456; 435/320.1 C12N015/861.

☐ 33. 20020091246 . 28 Feb 01. 11 Jul 02. Dendritic cell co-stimulatory molecules. Pardoll, Drew M., et al. 536/23.2; 435/320.1 435/372 435/69.3 435/69.7 C07H021/04 C12P021/04 C12N005/08.

☐ 34. 20020081736 . 01 Nov 01. 27 Jun 02. Nucleic acid delivery. Conroy, Susan E., et al. 435/455; 514/44 514/53 514/58 A61K048/00 C12N015/87 A61K031/715.

☐ 35. 20020077313 . 01 Oct 01. 20 Jun 02. Methods and compositions for the diagnosis and treatment of cancer. Clayman, Gary L.. 514/44; 424/93.21 435/320.1 A61K048/00 C12N015/861.

☐ 36. 20020076395 . 23 Dec 98. 20 Jun 02. MODIFIED ADIPOSE TISSUE AND RELATED IMPLANTS AND METHODS. CRYSTAL, RONALD G., et al. 424/93.2; A01N063/00.

☐ 37. 20020068049 . 06 Dec 00. 06 Jun 02. Tissue specific adenoviral vectors. Henderson, Daniel R., et al. 424/93.21; 435/235.1 435/320.1 A61K048/00 C12N015/861.

☐ 38. 20020052025 . 08 Jun 01. 02 May 02. RTVP based compositions and methods for the treatment of prostate cancer. Thompson, Timothy C., et al. 435/69.3; 435/184 435/320.1 435/325 536/23.2 C12N009/99 C07H021/04 C12P021/02 C12N005/06.

☐ 39. 20020042139 . 31 May 01. 11 Apr 02. Methods and compositions for efficient gene transfer using transcomplementary vectors. Higginbotham, James N., et al. 435/457; C12N015/861.

☐ 40. 20020037280 . 03 May 01. 28 Mar 02. Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof. Lieber, Andre, et al. 424/93.21; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

☐ 41. 20020037274 . 01 Oct 99. 28 Mar 02. SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS. WILLIAMS, ANGELICA, et al. 424/93.2; 435/320.1 435/325 435/375 514/44 A61K048/00 C12N005/06 C12N015/861.

☐ 42. 20020031823 . 04 Jun 01. 14 Mar 02. Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene. Brough, Douglas E., et al. 435/320.1; 514/44 A61K048/00

C12N015/86.

-
- ☐ 43. 20010044420 . 31 Jul 01. 22 Nov 01. Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms. Nielsen, Loretta Lynn, et al. 514/44; 514/50 A61K048/00 A61K031/7072.
-
- ☐ 44. 20010044413 . 30 Nov 00. 22 Nov 01. In situ bioreactors and methods of use thereof. Pierce, Glenn, et al. 514/44; A61K048/00.
-
- ☐ 45. 20010037016 . 15 Dec 00. 01 Nov 01. Methods and compositions for screening for angiogenesis modulating compounds. Ning, Zhang, et al. 536/23.1; C07H021/02 C07H021/04.
-
- ☐ 46. 20010033833 . 08 Dec 00. 25 Oct 01. Method of administering adenovirus. Schraa, Edwin Oscar, et al. 424/93.2; A61K048/00.
-
- ☐ 47. 20010016192 . 28 Oct 97. 23 Aug 01. RECOMBINANT ADENOVIRAL VECTOR AND METHOD OF USE. GREGORY, RICHARD J., et al. 424/93.2; 424/93.6 435/320.1 435/455 435/456 435/69.1 A61K048/00 C12N015/861.
-
- ☐ 48. 20010010933 . 29 Jan 01. 02 Aug 01. Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus. Brough, Douglas E., et al. 435/320.1; 424/93.21 435/235.1 A61K048/00 C12N015/09 C12N007/01.
-
- ☐ 49. 20010010814 . 09 Sep 99. 02 Aug 01. ADENOVIRAL VECTOR ENCODING PRO-APOPTOTIC BAX GENE AND USES THEREOF. CURIEL, DAVID T., et al. 424/93.1; 514/44 A61K048/00.
-
- ☐ 50. 20010006633 . 19 Apr 99. 05 Jul 01. ADENOVIRUS-CHEMOTHERAPEUTIC COMBINATION FOR TREATING CANCER. KIRN, DAVID. 424/93.6; 435/320.1 514/44 A61K048/00 A61K031/70.
-
- ☐ 51. 20010006629 . 24 Nov 99. 05 Jul 01. RECOMBINANT ADENOVIRAL VECTOR AND METHODS OF USE. GREGORY, RICHARD J., et al. 424/93.1; 424/93.2 424/93.6 435/320.1 514/44 A61K048/00 C12N015/861.
-
- ☐ 52. 6531456 . 28 Aug 00; 11 Mar 03. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman; Gary J., et al. 514/44; 424/199.1 424/93.2 435/235.1 435/320.1 435/455. A61K048/00 A61K031/00 C12N015/63 C12N015/74.
-
- ☐ 53. 6521602 . 01 Mar 00; 18 Feb 03. Anti-neoplastic compositions and uses thereof. Patel; Salil, et al. 514/44; 424/93.2 435/320.1 435/455 435/456 536/23.1 536/23.4 536/23.72. A61K048/00 C12N015/62 C12N015/85 C12N015/861 C12N015/867 C12N015/869.
-
- ☐ 54. 6511847 . 21 Sep 00; 28 Jan 03. Recombinant p53 adenovirus methods and compositions. Zhang; Wei-Wei, et al. 435/320.1; 435/235.1 435/69.1 536/23.1 536/23.72 536/24.1. C12N015/861 C07H021/04.
-
- ☐ 55. 6511676 . 05 Nov 99; 28 Jan 03. Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes. Boulikas; Teni. 424/450; 264/4.1 264/4.3. A61K009/127.
-
- ☐ 56. 6489305 . 08 May 98; 03 Dec 02. Methods and compositions for the treatment of ocular diseases. Demers; G. William. 514/44; 424/93.2 435/320.1. A61K048/00.
-

- ☐ 57. 6475480 . 06 Jul 99; 05 Nov 02. Use of adenoviral E4 reading frames to improve expression of a gene of interest. Mehtali; Majid, et al. 424/93.2; 435/235.1 435/320.1 435/440 435/455 435/456 514/44. A01N063/00 A01N043/04 C12N015/00 C12N007/00 C12N015/63.
-
- ☐ 58. 6464976 . 31 Aug 00; 15 Oct 02. Methods and compositions for reducing immune response. LaFace; Drake M., et al. 424/140.1; 424/131.1 424/159.1 424/233.1 424/278.1 424/93.1 435/7.1 514/885 530/351 604/4.01 604/5.01 604/5.02. A61K039/00 A61K045/00 A61K039/395 A61M037/00 G01N033/53.
-
- ☐ 59. 6451979 . 12 May 98; 17 Sep 02. Methods of treatment using NBS-1, antibodies and proteins thereto, and uses of the antibodies. Kaelin; William, et al. 530/387.1; 435/810 530/387.3 530/388.1 530/388.2 530/388.8 530/388.85. C07K016/00 C12P021/08.
-
- ☐ 60. 6451840 . 04 Dec 98; 17 Sep 02. Regulation of T cell-mediated immunity by tryptophan. Munn; David, et al. 514/419; 424/278.1. C07D401/02 C07D209/10 A61K031/405 A61K043/38.
-
- ☐ 61. 6436394 . 11 Jul 00; 20 Aug 02. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/366 435/369 435/371 435/455 435/456 435/457. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
- ☐ 62. 6436393 . 29 Apr 99; 20 Aug 02. Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof. Bilbao; Guadalupe, et al. 424/93.2; 424/93.21 424/93.6 435/320.1 435/325 435/455 514/44. A01N063/00 A01N043/04 C12N015/00 C12N005/00 C12N015/63.
-
- ☐ 63. 6432680 . 01 May 00; 13 Aug 02. Sequence and method for genetic engineering of proteins with cell membrane translocating activity. Lin; Yao-Zhong, et al. 435/69.7; 435/193 435/252.3 435/320.1 514/12 514/2 530/300 530/350. C12P021/06 C07H021/02 C12N015/00 A61K038/00.
-
- ☐ 64. 6429298 . 13 Oct 99; 06 Aug 02. Assays for identifying functional alterations in the p53 tumor suppressor. Ellington; Andrew D., et al. 536/23.1; 424/277.1 424/278.1 435/440 435/69.1 530/300 530/350. C07H021/02 C12N015/00 C07K001/00 A61K045/00 A61K039/00.
-
- ☐ 65. 6410010 . 29 Oct 93; 25 Jun 02. Recombinant P53 adenovirus compositions. Zhang; Wei-Wei, et al. 424/93.2; 424/93.1 424/93.6 435/320.1. A61K048/00 C12N015/861.
-
- ☐ 66. 6395876 . 04 Dec 98; 28 May 02. High-affinity tryptophan transporter. Munn; David, et al. 530/350;. C07K014/705 C07K014/47.
-
- ☐ 67. 6395712 . 19 Mar 97; 28 May 02. Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy. Hung; Mien-Chie, et al. 514/44; 424/649 514/449. A01N043/02 A01N043/04 A61K031/70 A61K033/24.
-
- ☐ 68. 6391630 . 01 Mar 99; 21 May 02. Plasmids that encode green fluorescent protein. Fattaey; Ali. 435/320.1; 435/252.3 435/456. C12N015/00.
-
- ☐ 69. 6333194 . 19 Jan 00; 25 Dec 01. Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof. Levy; Robert J., et al. 435/450; 424/1.25 424/1.33 424/1.53 424/497 435/6 536/23.1 536/3. C12N015/63 C12Q001/68 A61K051/00 C08B037/04 C07H021/02.
-
- ☐ 70. 6331284 . 08 Jun 00; 18 Dec 01. P202 is a tumor suppressor. Hung; Mien-Chie, et al. 424/1.11; 424/93.1 424/93.2 424/93.6 435/320.1 435/455 435/456 435/458 514/2 514/44 530/350 536/23.1 536/23.5 536/24.1. A61K051/00 A61K048/00 A61K038/21 A61K031/711.

-
- ☐ 71. 6326356. 18 Oct 96; 04 Dec 01. Suppression of neu overexpression using a mini-E1A gene. Hung; Mein-Chie, et al. 514/44; 424/450 424/93.2 424/93.6. A61K031/70 A61K048/00 A61K009/127 A01N063/00.
-
- ☐ 72. 6306833. 10 May 00; 23 Oct 01. Methods and compositions for inducing tumor-specific cytotoxicity. Hochberg; Abraham, et al. 514/44; 435/320.1 435/325 435/375 435/6 435/69.1. A01N043/04 A61K031/70 C12Q001/68 C12N015/00 C12N005/00.
-
- ☐ 73. 6300492. 14 Jul 00; 09 Oct 01. Modulation of IAPs for the diagnosis and antisense treatment of proliferative disease. Korneluk; Robert G., et al. 536/24.5; 435/91.1 536/23.1 536/24.3 536/24.31 536/24.33. A61K048/00 C07H021/04 C07H021/02 C12P019/34.
-
- ☐ 74. 6271207. 19 Oct 98; 07 Aug 01. Enhanced expression of transgenes. Cristiano; Richard J., et al. 514/44; 424/93.2 435/320.1 435/455 435/458. A61K048/00.
-
- ☐ 75. 6262032. 17 Jul 97; 17 Jul 01. Method of destroying hyperproliferative cells by combined p53 and taxoid treatment. Tocque; Bruno. 514/44; 424/93.2 424/93.21 435/320.1. A61K048/00 A61K035/00 C12N015/63.
-
- ☐ 76. 6254862. 02 Mar 98; 03 Jul 01. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little; Andrew S., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/370 435/455 435/456 435/5 435/6. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
- ☐ 77. 6248558. 04 Nov 98; 19 Jun 01. Sequence and method for genetic engineering of proteins with cell membrane translocating activity. Lin; Yao-Zhong, et al. 435/69.1; 435/320.1 514/12 536/23.1. C12P021/06 C07H021/02 C12N015/00 A61K038/00.
-
- ☐ 78. 6248351. 15 Jul 98; 19 Jun 01. Human PEA3 is a tumor suppressor for cancer cells. Xing; Xiangming, et al. 424/450; 424/93.2 424/93.6 435/320.1 435/325 435/375 435/455 435/456 514/2 514/44 536/23.1 536/23.5. A61K048/00 A61K038/17 A61K031/711 C12N015/867 C12N015/63.
-
- ☐ 79. 6225113. 04 Dec 98; 01 May 01. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus. Brough; Douglas E., et al. 435/320.1; C12N015/86.
-
- ☐ 80. 6221848. 11 May 98; 24 Apr 01. Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy. Greenberger; Joel S.. 514/44; 424/93.2 424/93.21 435/267 435/320.1 435/455. A01N043/04 A01N063/00 C12N015/00 C12N015/63 C07G017/00.
-
- ☐ 81. 6218180. 10 Mar 99; 17 Apr 01. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman; Gary J., et al. 435/320.1; 424/199.1 424/93.2 435/235.1. C12N015/63 C12N007/00 A61K048/00 A61K038/00.
-
- ☐ 82. 6210939. 25 Oct 94; 03 Apr 01. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 435/456; 435/252.3 435/320.1 435/363 435/366 435/370 435/371. C12N005/10 C12N015/10 C12N015/63 C12N015/86.
-
- ☐ 83. 6207648. 17 Jul 98; 27 Mar 01. Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy. Waxman; David J., et al. 514/44; 435/320.1 435/455 536/23.2 536/23.4. A01N043/04 C12N015/00 C12N015/63 C07H021/04.
-

- ☐ 84. 6197293 . 02 Mar 98; 06 Mar 01. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/371 435/375 435/455 435/456 435/5 435/6. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
- ☐ 85. 6143290 . 07 Apr 94; 07 Nov 00. Tumor regression by adenovirus expression of wild-type p53. Zhang; Wei-Wei, et al. 424/93.2; 424/93.6 435/320.1. A01N063/00 A01N048/00 C12N015/00.
-
- ☐ 86. 6133437 . 13 Feb 97; 17 Oct 00. Modulation of IAPs for the treatment of proliferative diseases. Korneluk; Robert G., et al. 536/24.5; 435/325 435/375 435/6 435/91.1 536/23.1 536/24.3 536/24.31 536/24.33. A61K048/00 C07H021/04 C07H021/02 C12P019/34.
-
- ☐ 87. 6110744 . 12 Nov 97; 29 Aug 00. Diminishing viral gene expression by promoter replacement. Fang; Bingliang, et al. 435/456; 435/320.1 536/23.1 536/23.5 536/23.7 536/23.72 536/24.1. C12N015/64 C12N015/34 C12N015/12.
-
- ☐ 88. 6107041 . 16 Dec 98; 22 Aug 00. Detection and modulation of IAPS for the diagnosis and treatment of proliferative disease. Korneluk; Robert G., et al. 435/6; 435/320.1 435/325 435/375 435/69.1 536/23.1 536/23.5. C12Q001/68 C12N015/00 C12N015/85 C12N015/86 C12N015/63 C07H021/04.
-
- ☐ 89. 6087164 . 01 Oct 98; 11 Jul 00. Methods and compositions for inducing tumor-specific cytotoxicity. Hochberg; Abraham, et al. 435/320.1; 435/325 435/6 435/91.4 536/23.1. C12N015/63 C12N015/11 C12Q001/68.
-
- ☐ 90. 6069134 . 17 Oct 97; 30 May 00. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/458 435/69.1. A61K048/00.
-
- ☐ 91. 6060247 . 18 Nov 97; 09 May 00. Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth. Miller; Freda D., et al. 435/6; 435/377 435/456. C12Q001/68.
-
- ☐ 92. 6030956 . 23 Oct 97; 29 Feb 00. Combination gene therapy for human cancers. Bouliskas; Teni. 514/44; 428/402.2 435/320.1 536/23.2 536/23.5 536/24.1. C12N015/00 A01N043/04 C07H021/04 B32B005/16.
-
- ☐ 93. 5972899 . 25 Jan 96; 26 Oct 99. Apoptosis induced by Shigella IpaB. Zychlinsky; Arturo, et al. 514/44; 424/93.2 435/320.1 435/455. A61K048/00 C12N015/31 C12N015/85.
-
- ☐ 94. 5952221 . 05 Mar 97; 14 Sep 99. Adeno-associated virus vectors comprising a first and second nucleic acid sequence. Kurtzman; Gary J., et al. 435/320.1; 424/93.1 435/325 514/44. C12N015/63 C12N015/85 A61K048/00.
-
- ☐ 95. 5932210 . 28 Oct 97; 03 Aug 99. Recombinant adenoviral vector and methods of use. Gregory; Richard J., et al. 424/93.2; 424/93.6 435/320.1. A61K048/00 C12N015/86.
-
- ☐ 96. 5876711 . 31 May 96; 02 Mar 99. Methods and compositions for determining the tumor suppressor status of cells. Fattaey; Ali. 424/93.2; 435/5 435/6 514/44. A01N063/00 C12Q001/70 C12Q001/68.
-
- ☐ 97. 5837531 . 13 May 96; 17 Nov 98. Recombinant adenoviruses for gene therapy in cancers. Dedieu; Jean-Fran.cedilla.ois, et al. 435/320.1; 424/93.2 435/325 435/69.1 435/91.4 514/44. C12N015/63.

☐ 98. 5831062 . 08 May 97; 03 Nov 98. Use of the human interferon consensus gene for gene therapy. Taylor; Milton W., et al. 536/23.52; 536/24.1. E07H021/04.

☐ 99. 5814315 . 01 Jun 95; 29 Sep 98. Methods for the suppression of neu mediated phenotype in tumors. Hung; Mien-Chie, et al. 424/93.2; 424/450 424/93.6 514/44. A61K048/00 A61K009/127 A01N063/00 C12N015/00.

☐ 100. 5747469 . 25 Apr 94; 05 May 98. Methods and compositions comprising DNA damaging agents and p53. Roth; Jack A., et al. 514/44; 435/320.1 435/375 514/2. A61K048/00 C12N005/00 C12N015/00.

Generate Collection

Print

Terms	Documents
L5 and pharmaceutic\$	101

[Previous Page](#)[Next Page](#)

```
-----  
? set hi ;set hi  
HILIGHT set on as ''  
HILIGHT set on as ''  
? begin 5,6,55,154,155,156,312,399,biotech,biosci  
>>>      135 is unauthorized
```

Set	Items	Description
? s adenovir?	(5n)	vector?
	191031	ADENOVIR?
	1161624	VECTOR?
S1	42285	ADENOVIR? (5N) VECTOR?
? s s1 and p53		
	42285	S1
	261239	P53
S2	2660	S1 AND P53
? s s2 and CMV		
	2660	S2
	74176	CMV
S3	122	S2 AND CMV

? s 3 and pharmaceut?

Processing

Processed 10 of 34 files ...

Processing

Completed processing all files

19152439 3

1353990 PHARMACEUT?

S4 193184 3 AND PHARMACEUT?

? s s3 and pharmaceutical?

122 S3

1329211 PHARMACEUTIC?

S5 3 S3 AND PHARMACEUTIC?

? d s5/3/1-3

Display 5/3/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

132344118 CA: 132(26)344118y PATENT

Adenoviral vectors with E1B deletion replicated in tumor cells and their use in cancer therapy

INVENTOR(AUTHOR): Howe, John A.; Perry, Stuart T.

LOCATION: USA

ASSIGNEE: Canji, Inc.

PATENT: PCT International ; WO 200029573 A2 DATE: 20000525

APPLICATION: WO 99US26003 (19991117) *US 195748 (19981118)

PAGES: 46 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/12A; C12N-015/34B; C12N-015/861B; C07K-014/075B; C07K-014/47B; A61K-038/05B; A61K-048/00B; A61P-035/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE;

-more-

?

Display 5/3/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 5/3/2 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

132278193 CA: 132(21)278193r PATENT
Methods and compositions to induce antitumor immune response through the
expression of dendritic cell chemoattractants
INVENTOR(AUTHOR): Laface, Drake M.
LOCATION: USA
ASSIGNEE: Canji, Inc.
PATENT: PCT International ; WO 200022124 A2 DATE: 20000420
APPLICATION: WO 99US21454 (19991014) *US 173203 (19981015)
PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/12A;
C07K-014/47B; C07K-014/52B; A61K-048/00B; A61P-035/00B
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH;
CN; CR; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP;
KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; NO; NZ; PL; PT;
RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ;
BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;

-more-

?

Display 5/3/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 5/3/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0285476 DBR Accession No.: 2002-07323 PATENT
Producing antibodies to an antigen in an avian species useful for
determining the proteomic profile of DNA sequences in a biological
sample for the discovery of new drug targets and drugs - adeno
virus-mediated **p53** tumor suppressor and Ras expression in
hybridoma cell culture and plasmid-mediated hepatitis B-X antigen gene
transfer for monoclonal antibody production in fowl

AUTHOR: DUAN L
PATENT ASSIGNEE: GENWAY BIOTECH INC 2001
PATENT NUMBER: WO 200188162 PATENT DATE: 20011122 WPI ACCESSION NO.:
2002-089858 (200212)
PRIORITY APPLIC. NO.: US 573442 APPLIC. DATE: 20000516
NATIONAL APPLIC. NO.: WO 2001US14817 APPLIC. DATE: 20010507
LANGUAGE: English

- end of display -

? s s2 and pharmaceutic?

2660 S2

1329211 PHARMACEUTIC?

S6 99 S2 AND PHARMACEUTIC?

? rd s6

...examined 50 records (50)

...completed examining records

S7 92 RD S6 (unique items)

? s s7 not py>1994

Processing

Processed 10 of 34 files ...

Processing

Processing

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

Processed 20 of 34 files ...

Completed processing all files

92 S7
51917695 PY>1994
S8 1 S7 NOT PY>1994
? d s8/9/1

Display 8/9/1 (Item 1 from file: 315)
DIALOG(R)File 315:ChemEng & Biotec Abs
(c) 2003 DECHEMA. All rts. reserv.

333529 CEABA Accession No.: 25-03-004850 DOCUMENT TYPE: Journal
Title: New gene therapy company targets gene mutation associated with
cancer.

CORPORATE SOURCE: Canji Inc. San Diego, CA 92121 USA
JOURNAL: Biotechnology News, Volume: 13, Issue: 21, Page(s): 4-5
CODEN: BINWEY ISSN: 02733226
PUBLICATION DATE: 10 Sep 1993 (930910) LANGUAGE: English

ABSTRACT: Canji Inc is designing gene therapies to restore the cancer
suppressor genes that express mutated, inactive versions of these
genes. Preclinical data has indicated that restoring mutated **p53**
and Rb genes is sufficient to stop malignancy (leukaemia in mice). The
p53 gene encodes for a cell cycle regulatory protein; mutation in
this gene and the resulting loss of cell cycle regulation means
uncontrolled cell growth. In a separate trial, the Rb gene injected
locally into a subcutaneous human tumour in mice halted growth of the
tumour. An iv injection halted tumour growth at a distant site. Canji

-more-

?
Display 8/9/1 (Item 1 from file: 315)
DIALOG(R)File 315:ChemEng & Biotec Abs
(c) 2003 DECHEMA. All rts. reserv.

wants to repeat the tests with an **adenoviral vector** which
is safer for human use. It then wants to start trials in 1994, going
first for colorectal cancer that has metastasized to the liver.

DESCRIPTORS: English; disease therapy; gene therapy; cancer; tumour;
gastrointestinal cancer; cancer, gastrointestinal; clinical trial;
genetic manipulation; mouse; leukaemia; cell growth

SECTION: Business News (51)

SECTION CROSS-REFERENCE: **Pharmaceuticals** (58); Genetic
Manipulation (53)

DECHEMA CLASSIFICATION: Economics (915); CHEMICAL AND PRODUCTION
ECONOMICS (15); High-molecular products (enzymes, hormones,
peptides, etc.) (9435); Biology, Microbiology, Molecular Biology
(classification, taxonomy, morphology, physiology, strain improvement,
genetics, ecology, inoculum, maintenance, storage) (914)

- end of display -

? e au=zhang, wei-wei

Ref	Items	Index-term
E1	61	*AU=ZHANG, WEI-WEI
E2	10	AU=ZHANG, WEI-WEN
E3	1	AU=ZHANG, WEI-XI
E4	39	AU=ZHANG, WEI-XIAN
E5	1	AU=ZHANG, WEI-XIANG
E6	6	AU=ZHANG, WEI-XIN
E7	4	AU=ZHANG, WEI-XING
E8	1	AU=ZHANG, WEI-XIONG
E9	4	AU=ZHANG, WEI-XU
E10	5	AU=ZHANG, WEI-YA
E11	2	AU=ZHANG, WEI-YAN
E12	16	AU=ZHANG, WEI-YANG

Enter P or PAGE for more

? e au=zhang Wei

Ref	Items	Index-term
E1	1	AU=ZHANG WEDAO
E2	5	AU=ZHANG WEHEI
E3	1495	*AU=ZHANG WEI
E4	2	AU=ZHANG WEI BIN
E5	1	AU=ZHANG WEI BING
E6	2	AU=ZHANG WEI CHEN NAN
E7	2	AU=ZHANG WEI CUO
E8	2	AU=ZHANG WEI DANG
E9	1	AU=ZHANG WEI DONG
E10	3	AU=ZHANG WEI GUE
E11	10	AU=ZHANG WEI GUO
E12	1	AU=ZHANG WEI HAN

Enter P or PAGE for more

? p

Ref	Items	Index-term
E13	8	AU=ZHANG WEI HONG
E14	2	AU=ZHANG WEI HUA
E15	4	AU=ZHANG WEI JIAN
E16	2	AU=ZHANG WEI JUN
E17	2	AU=ZHANG WEI LIN
E18	15	AU=ZHANG WEI MIN
E19	3	AU=ZHANG WEI MING
E20	4	AU=ZHANG WEI NIAN
E21	1	AU=ZHANG WEI QIN
E22	2	AU=ZHANG WEI QIU
E23	5	AU=ZHANG WEI SEN
E24	2	AU=ZHANG WEI V

Enter P or PAGE for more

? p

Ref	Items	Index-term
E25	2	AU=ZHANG WEI W
E26	32	AU=ZHANG WEI WEI
E27	2	AU=ZHANG WEI XIE
E28	30	AU=ZHANG WEI YUAN
E29	2	AU=ZHANG WEI YUN
E30	4	AU=ZHANG WEI Z
E31	4	AU=ZHANG WEI ZHENG
E32	2	AU=ZHANG WEI ZHONG
E33	3	AU=ZHANG WEI-BIN
E34	4	AU=ZHANG WEI-BING
E35	2	AU=ZHANG WEI-CAI
E36	3	AU=ZHANG WEI-CHEN

Enter P or PAGE for more

? e au=roth jack

Ref	Items	Index-term
E1	6	AU=ROTH J-P
E2	805	AU=ROTH JA
E3	29	*AU=ROTH JACK
E4	546	AU=ROTH JACK A
E5	2	AU=ROTH JACK R
E6	4	AU=ROTH JAKOB
E7	11	AU=ROTH JAMES
E8	126	AU=ROTH JAMES A
E9	6	AU=ROTH JAMES C

E10 26 AU=ROTH JAMES D
E11 35 AU=ROTH JAMES H
E12 1 AU=ROTH JAMES M

Enter P or PAGE for more
? e au= roth j a

Ref	Items	Index-term
E1	4680	AU=ROTH J
E2	1	AU=ROTH J -P
E3	2248	*AU=ROTH J A
E4	1	AU=ROTH J A.
E5	1	AU=ROTH J A; +FANG B
E6	15	AU=ROTH J B
E7	67	AU=ROTH J C
E8	56	AU=ROTH J D
E9	49	AU=ROTH J E
E10	22	AU=ROTH J F
E11	29	AU=ROTH J G
E12	218	AU=ROTH J H

Enter P or PAGE for more
?



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)